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Abstract 25 
Combating antimicrobial resistance (AMR) is one of the most serious public health 26 
challenges facing society today. The development of new antibiotics or alternative 27 
techniques that can help combat AMR is a priority of many governments across the globe. 28 
Antimicrobial Photodynamic Therapy (APDT) is one such technique that has received 29 
considerable attention but is limited by the ability of light to penetrate deeply through human 30 
tissue reducing its effectiveness when used to treat deeply seated infections. The related 31 
technique sonodynamic therapy (SDT) has the potential to overcome this limitation given the 32 
ability of low intensity ultrasound to penetrate deeply through human tissue. In this 33 
manuscript, we have prepared a Rose Bengal-antimicrobial peptide conjugate for use in 34 
antimicrobial SDT (ASDT). We evaluate the ASDT efficacy of this conjugate upon irradiation 35 
with ultrasound in both S. aureus and P. aeruginosa bacterial strains. The ability of the 36 
conjugate to preferentially target bacteria over mammalian cells was also determined as was 37 
the ability of ultrasound to enhance the uptake of sensitisers through bacterial biofilms. 38 
Combined, the results from this study highlight ASDT as a targeted broad-spectrum modality 39 
with potential for the treatment of deeply-seated bacterial infections. 40 
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  44 
1. Introduction 45 
Although the threat of antibiotic resistance has been prophesised for years, the issue has 46 
recently been described as an “apocalyptic scenario” by the UK’s chief medical officer 47 
representing “one of the most significant public health challenges facing society today”.1 48 
With 80% of gonorrhoeal infections now resistant to antibiotics and a reported 440,000 new 49 
cases of drug resistant tuberculosis per year, it has been suggested that we are fast 50 
approaching a post-antibiotic era.2,3  This threat is not confined to systemic infections with 51 
the problem equally apparent in localised wound infection. Surgical wound infections 52 
account for 25% of nosocomial infections and result in a 2.5 times longer hospital stay with 53 
additional costs of ~£5,000 per patient.4 Diabetic foot ulcers (DFU) and burns are equally 54 
problematic. In the US alone, 25 million people are estimated to have Diabetes Mellitus and 55 
15-25% will develop DFU during their lifetime.5 Over 50% of these ulcerations will become 56 
infected resulting in increased hospital admissions, amputation rates and mortality with an 57 
estimated one in six patients dying within 1 year of their infection.6 The overall impact of this 58 
on both the patient and health service provider is significant and highlights an urgent need 59 
for alternative therapies. 60 
 61 
Photodynamic therapy (PDT) is a clinical treatment that uses a combination of light, 62 
molecular oxygen and a photosensitising drug to generate a cytotoxic effect.7  When the 63 
sensitiser absorbs light of an appropriate wavelength, the excited triplet state interacts with 64 
molecular oxygen by electron (Type I) or energy (Type II) transfer processes that result in 65 
the generation of cytotoxic singlet oxygen and other reactive oxygen species (ROS). 66 
Because of the high reactivity and short half-life (0.04 µs) of singlet oxygen, its diffusion 67 
radius is less than 20 nm meaning only cells close to the site of its generation are affected.8 68 
While predominantly used in the treatment of cancer, antimicrobial PDT (APDT) has also 69 
received considerable interest for the treatment of microbial infections.9-11 The major 70 
attraction of APDT over conventional antibiotics is that multiple antibiotic resistant (AMR) 71 
strains are as easily killed as native strains and because it results in the production of 72 
multiple forms of ROS,  resistance to PDT is less likely to occur.12 However, PDT is severely 73 
limited by the inability of light to penetrate to depth through mammalian tissue. This is due to 74 
endogenous pigments such as haem or melanin competing for light absorption with the 75 
sensitiser and is a particular problem in localised infection where the wound area may be 76 
severely discoloured due to bruising or inflammation.13 Currently approved sensitisers 77 
absorb in the visible region of the electromagnetic spectrum limiting light penetration to only 78 
a few millimetres and reducing the ability of APDT to eradicate bacteria localised deeper 79 
within infected wounds.14 80 
 81 
In recent years it has been demonstrated that many of the existing clinically-used 82 
photosensitisers can be ‘activated’ by ultrasound, although the precise mechanism(s) by 83 
which this occurs remain(s) unknown.15-18 This approach has become known as 84 
Sonodynamic Therapy (SDT). Ultrasound can be tightly focused with penetration in soft 85 
tissue up to several tens of centimetres depending on the frequency used.19 The efficacy of 86 
SDT as an anti-cancer treatment has been demonstrated in numerous pre-clinical and 87 
clinical studies.20-23 Antimicrobial SDT (ASDT) has also emerged as an active area of 88 
research but reports to date have used clinically unsuitable ultrasound equipment / 89 
conditions and have not explored the potential damage of the treatment on host tissue.24-26 90 
As is the case for APDT, a major challenge for ASDT is specifically targeting the sensitiser to 91 
bacterial cells to reduce collateral damage to host tissue. A surgical site infection can be 92 
defined as a suppurating wound containing a variety of components such as host tissue 93 
(skin cells, muscle cells and extracellular matrix components), immune cells and bacterial 94 
cells (both live and dead).27,28 The bacterial load can be as low as 105 bacteria (i.e. µg 95 
quantities) per gram of tissue meaning the majority of this complex environment is host 96 
tissue essential in the healing process.29 As the cytotoxic agent(s) involved in APDT / ASDT 97 
are indiscriminate in their action on host or bacterial cells, it is imperative the sensitiser is 98 
preferentially directed to bacterial cells rather than host cells before activation with light or 99 
ultrasound. One method to achieve sensitiser selectivity is to exploit the differential binding 100 
exhibited by cationic species to the cell wall of bacterial and mammalian cells. For example, 101 
it has been demonstrated that light irradiation of wounds in mice treated with a poly-L-lysine-102 
chlorin(e6) conjugate exhibited a greater bacterial kill and less host tissue damage than the 103 
free sensitiser alone.30 Similarly, when the antimicrobial peptide (KLAKLAK)2 was conjugated 104 
to the sensitiser eosin, its antimicrobial photodynamic activity was enhanced with negligible 105 
photo-damage observed to normal cells.31 106 
 107 
Inspired by these results, we have developed a Rose Bengal-(KLAKLAK)2 conjugate for use 108 
in targeted ASDT. The potential of the conjugate to generate ROS during exposure to 109 
ultrasound was determined in cell-free solution and the antimicrobial efficacy was 110 
established using both Staphylococcus aureus and Pseudomonas aeruginosa as target 111 
microorganisms. The ability of the conjugate to preferentially target bacteria over healthy 112 
mammalian cells was also determined. Finally, the effectiveness of ultrasound to enhance 113 
the diffusion of sensitisers through bacterial biofilms was investigated.  114 
 115 
  116 
2. Results and Discussion 117 
The Rose Bengal-C(KLAKLAK)2 conjugate was prepared by first synthesising the 118 
C(KLAKLAK)2 peptide using Fmoc solid phase peptide synthesis on Rink Amide resin. In 119 
parallel, a carboxylic acid derivative of Rose Bengal was also prepared by reacting Rose 120 
Bengal with 1-bromooctanoic acid. This carboxylic acid derivative was added to the N-121 
terminus of C(KLAKLAK)2 while still on the resin using standard peptide coupling reagents 122 
(i.e. HOBt / TBTU).The Rose Bengal-C(KLAKLAK)2 conjugate was then cleaved from the 123 
resin and purified using preparative reverse phase HPLC. Product formation was confirmed 124 
using MALDI-TOF and positive electrospray mass spectrometry (Fig S1).   125 
 126 
The ability of the Rose Bengal-C(KLAKLAK)2 conjugate to generate ROS upon exposure to 127 
low intensity ultrasound was determined using the chromogenic ROS probe 1,3-128 
diphenylisobenzofuran (DPBF).32 DPBF has an intense absorbance band centred at 410 nm 129 
in its native furan form but is readily bleached by ROS to the corresponding di-ketone. This 130 
conversion to the di-ketone is accompanied by a loss in absorbance at 410 nm that can be 131 
used to determine the amount of ROS produced. Solutions containing either Rose Bengal or 132 
Rose Bengal-C(KLAKLAK)2 and DPBF were treated with ultrasound for 30 min and the 133 
DPBF absorbance at 410 nm measured every 5 min. The results are shown in figure 1 and 134 
show a significant reduction in DPBF absorbance for both Rose Bengal or Rose Bengal-135 
C(KLAKLAK)2 treated with ultrasound relative to the controls indicating efficient ROS 136 
production in the ultrasonic field. In addition, the almost identical profile observed for both 137 
Rose Bengal and Rose Bengal-C(KLAKLAK)2 suggests the presence of the peptide does not 138 
inhibit ultrasound-induced ROS production by the sensitiser. 139 
 140 
To determine the antimicrobial potential of this ROS generation, two candidate bacterial 141 
strains, Gram positive S. aureus and Gram negative P. aeruginosa, were subjected to ASDT 142 
treatment. In each case, suspensions containing 108 bacteria were added to the wells of a 143 
96-well plate and incubated with 10 µM Rose Bengal or Rose Bengal-C(KLAKLAK)2 for 30 144 
min. The wells were then treated with ultrasound from the underside of the plate for either 10 145 
min (S. aureus) or 6 min (P. aeruginosa). Following treatment, the number of viable bacteria 146 
remaining was determined and expressed as CFU/mL. The results, shown in figure 2, reveal 147 
that ultrasound treatment of S. aureus produces only a minor reduction (~0.5 log) in bacterial 148 
number that was not statistically significant.  Treatment of S. aureus with Rose Bengal-149 
C(KLAKLAK)2 in the absence of ultrasound produced an ~1 log reduction in bacterial 150 
number. This reduction was attributed to the antimicrobial effect from the AMP component of 151 
the Rose Bengal-C(KLAKLAK)2 conjugate as Rose Bengal alone in the absence of 152 
ultrasound produced no change in bacterial number (data not shown). The magnitude of this 153 
reduction is consistent with other literature where (KLAKLAK)2 alone has been shown to 154 
possess little activity against Gram positive bacteria.31 However, when Rose Bengal-155 
C(KLAKLAK)2 was combined with ultrasound treatment, a statistically significant 5 log 156 
reduction in bacterial number was observed. This suggests that the ROS generated upon 157 
interaction of ultrasound with the Rose Bengal component of Rose Bengal-C(KLAKLAK)2 158 
produces the desired antimicrobial effect. When this experiment was repeated using the 159 
same concentration of Rose Bengal (i.e. without AMP attached) and the same ultrasound 160 
conditions, the reduction in bacterial numbers was approximately one log less than for Rose 161 
Bengal-C(KLAKLAK)2 plus ultrasound. This difference, while not statistically significant, 162 
suggests the slight antimicrobial effect observed for Rose Bengal-C(KLAKLAK)2 alone (i.e. 163 
no ultrasound) complements the  ASDT effect of Rose Bengal.  164 
 165 
It is generally considered that PDT is more toxic to Gram positive than Gram negative 166 
bacteria and it has been suggested that this is due to structural differences in cell wall 167 
composition.33 Given that both the sensitisers used and the cytotoxic species generated (i.e. 168 
ROS) are the same in PDT and SDT, one would expect that Gram negative  bacteria would 169 
also be more difficult to kill using SDT. Indeed, when P. aeruginosa was treated with Rose 170 
Bengal and ultrasound, only a minor reduction in bacterial number was observed (~ 0.5 log) 171 
which was considerably lower than for S. aureus. However, when P. aeruginosa was treated 172 
with the Rose Bengal-C(KLAKLAK)2 conjugate and ultrasound the results were even more 173 
dramatic than for S. aureus, with a 7 log reduction in CFU observed (Fig.2b). This large 174 
reduction in bacterial number cannot be explained by the antimicrobial nature of the peptide 175 
alone as treatment of P. aeruginosa with Rose Bengal-C(KLAKLAK)2 in the absence of 176 
ultrasound  produced a much lower 3.5 log reduction in bacterial number, suggesting the 177 
peptide positions the sensitiser close enough to the bacteria to exert its cytotoxic effect 178 
during ultrasound irradiation. To probe this interaction further, we incubated suspensions of 179 
both S. aureus and P. aeruginosa with different amounts of the Rose Bengal-C(KLAKLAK)2 180 
conjugate and measured the zeta potential before and after conjugate addition. Both 181 
bacterial strains showed strongly negative zeta potentials (-42.0 and -27.0 mV respectively) 182 
which are consistent with literature precedent.34,35 Upon addition of increasing amounts of 183 
Rose Bengal-C(KLAKLAK)2, the net charge of both bacteria increased but with significantly 184 
different magnitudes (Fig.3). For example, addition of 10 µM Rose Bengal-C(KLAKLAK)2 to 185 
P. aeruginosa resulted in a 2.0 mV increase in zeta potential while for S. aureus an increase 186 
of 29.7 mV was observed. Indeed, only when 50 µM Rose Bengal-C(KLAKLAK)2 was added 187 
to P. aeruginosa did the charge become positive while for S. aureus this occurred after only 188 
10 µM. These results confirm a direct interaction between the positively charged peptide and 189 
negatively charged bacterial cell wall with P. aeruginosa requiring a significantly greater 190 
number of Rose Bengal-C(KLAKLAK)2 molecules to bind in order to titrate the more negative 191 
surface charge.  192 
 193 
Systemic delivery of sensitisers is not normally considered in APDT as damage to capillaries 194 
and host cells directly supplied by them is undesirable.36 Therefore, while local 195 
administration is preferred, this form of delivery still requires the sensitiser to be targeted to 196 
bacteria so that collateral damage to host tissue crucial to the healing process can be 197 
minimised. To determine the ability of Rose Bengal-C(KLAKLAK)2 to preferentially target 198 
bacteria over mammalian cells, solutions containing Rose Bengal or Rose Bengal-199 
C(KLAKLAK)2 were incubated with suspensions containing S. aureus, P. aeruginosa or 200 
human fibroblast (HS27) cells for either 10, 20  or 30 min. Following incubation, the 201 
suspensions were centrifuged, the cells lysed and the Rose Bengal concentration 202 
determined using UV-Vis spectroscopy. The results are shown in Fig 4 and reveal a 203 
significantly enhanced uptake of the Rose Bengal-C(KLAKLAK)2 in both bacteria compared 204 
to the Hs27 cells at the time points tested. Indeed, the uptake of Rose Bengal-C(KLAKLAK)2 205 
conjugate was also higher than Rose Bengal in both bacteria while it was generally lower in 206 
the Hs-27 cells which is ideal for bacterial targeting.  207 
 208 
The presence of biofilms is a significant challenge associated with the local delivery of 209 
sensitiser drugs as it can act as a barrier between the applied sensitiser and bacteria. With 210 
as many as 80% of SSI’s involving a microbial biofilm, strategies that can enhance 211 
dispersion of drugs through biofilms offer a significant advantage. It has been demonstrated 212 
that in addition to increasing the permeability of membranes through sonoporation, shear 213 
forces induced by ultrasound generates pores in the architecture of biofilms, enhancing the 214 
effectiveness of antibiotic treatment.37 To test this hypothesis, we generated P. aeruginosa 215 
biofilms on the surface of trans-well inserts and tested the diffusion of Rose Bengal through 216 
the biofilm in the presence and absence of ultrasound (Fig 5a). Preliminary data (Fig 5b) 217 
show that pre-treatment of the biofilm with low intensity ultrasound for 5 min before addition 218 
of Rose Bengal produced a 2.6-fold increase in sensitiser diffusion through the biofilm 219 
compared to the untreated biofilm control. These results suggest that ultrasound can 220 
facilitate the dispersion of sensitisers through biofilms and potentially improve the efficacy of 221 
ASDT. 222 
 223 
Having established the effectiveness of the SDT approach in vitro we were also interested if 224 
a similar effect would be observed in vivo. To determine this, wound abrasions (0.5 cm2) 225 
were established in the dorsum of Balb/c mice and inoculated with a bioluminescent strain of 226 
P. aeruginosa. Once the infection had established, bioluminescent images were recorded 227 
using an IVIS whole body imaging system. The wound was then treated with a PBS solution 228 
containing the Rose Bengal-C(KLAKLAK)2 conjugate (4.5mg/kg) and 10 min later exposed 229 
to ultrasound. Bioluminescent images were then recorded 1 h and 24 h after ultrasound 230 
treatment. Control groups involving no treatment or treatment with Rose Bengal-231 
C(KLAKLAK)2 or ultrasound alone were also undertaken for comparative purposes. 232 
Representative images of the mice are shown in figure 6 and reveal substantial reductions in 233 
bioluminescent intensity for mice treated with the conjugate alone or SDT, with the SDT 234 
image being less intense, particularly after 24h. In contrast, the bioluminescent intensity of 235 
the untreated and ultrasound only groups were substantially more intense than the Rose 236 
Bengal-C(KLAKLAK)2 or SDT treated animals. This pattern follows a similar trend to the 237 
results obtained for the in vitro experiments undertaken using P. aeruginosa where Rose 238 
Bengal-C(KLAKLAK)2 alone produced a modest 3.5 log reduction while SDT treatment 239 
resulted in a much greater 7 log reduction. It was also apparent from the images presented 240 
in Figure 6 that the size of the wound 24 h following SDT treatment was much smaller when 241 
compared to 1 h following SDT treatment suggesting a degree of wound healing, a feature 242 
that was not apparent in any of the other groups. While there is an obvious limitation in the 243 
small sample size used in these experiments, the results do suggest that SDT using Rose 244 
Bengal-C(KLAKLAK)2 is capable of substantially reducing bacterial burden in an in vivo 245 
model of localised infection.  Interestingly the results also suggest that our approach does 246 
not elicit any collateral damage on host tissues.   We are currently designing a larger animal 247 
study involving both MRSA and P. aeruginosa infection models and will report on this in due 248 
course. 249 
 250 
In conclusion, a Rose Bengal-C(KLAKLAK)2 conjugate has been prepared for use in 251 
targeted ASDT. A broad-spectrum ASDT effect was observed when the conjugate was used 252 
to treat S. aureus and P. aeruginosa in the presence of low intensity ultrasound. The 253 
conjugate also displayed improved uptake by these bacterial strains when compared to a 254 
mammalian cell line which promises to minimise damage to host tissue when considering in 255 
vivo ASDT applications. In addition, pre-treatment of a P. aeruginosa biofilm with low 256 
intensity ultrasound before application of Rose Bengal enhanced diffusion of the sensitiser 257 
through the biofilm. A preliminary pilot in vivo experiment provided qualitative evidence of a 258 
substantial reduction in bacterial burden without collateral damage to host tissues when a P. 259 
aeruginosa infected wound was treated with SDT using the Rose Bengal-C(KLAKLAK)2 260 
conjugate. Combined, these results suggest that ASDT using Rose Bengal-C(KLAKLAK)2 is 261 
an effective broad-spectrum antimicrobial technique with the potential to activate sensitisers 262 
at a much greater depth in human tissue than APDT enabling the treatment of more deep-263 
seated infections.  264 
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Figure 1   Plot of DPBF absorbance at 410 nm against time for solutions containing (i) Rose 416 
Bengal (ii) Rose Bengal-C(KLAKLAK)2 conjugate (iii) DPBF alone plus ultrasound treatment 417 
(iv) Rose Bengal plus ultrasound treatment and (v) Rose Bengal-C(KLAKLAK)2 conjugate plus 418 













































Figure 2  Plot of CFU/mL after treatment of (a) S. aureus and (b) P. aeruginosa with RB-438 
C(KLAKLAK)2 (P), Rose Bengal (RB)  with / without ultrasound (+/- U). [RB-C(KLAKLAK)2] = 439 
[RB] = 10 µM. Ultrasound conditions: 1 MHz, 3Wcm-2, 10 min, 50 % duty cycle for S. aureus 440 
and 1 MHz, 3Wcm-2, 6 min, 50 % duty cycle for P. aeruginosa. * represents P ≤ 0.05, ** 441 














































Figure 3  Plot of zeta potential for suspensions of P. aeruginosa (shaded columns) and S. 444 




























Figure 4 Plot of nmol of Rose Bengal per mg protein for suspensions of S. aureus (circles), 451 
P. aeruginosa (triangles) and HS27 RB cells (squares) incubated with RB (filled symbols) or 452 
RB-C(KLAKLAK)2 (open symbols) for 10, 20 or 30 mins. (# represents P ≤ 0.001 with respect 453 
to uptake by RB alone and P ≤ 0.001 with respect to RB-C(KLAKLAK)2 uptake in HS27 cells). 454 
(≠ represents P ≤ 0.01 with respect to uptake by RB alone and P ≤ 0.01 with respect to RB-455 

































Figure 5 (a) Schematic representation of biofilm diffusion experiment. P.aeruginosa biofilms 467 
were generated on transwell inserts. The inserts were placed in wells containing PBS buffer 468 
and the base of each well irradiated (or not) with low intensity ultrasound. RB solution was 469 
added to the donor insert and the concentration of RB in the receiving PBS solution 470 
determined  at various time points using UV-Vis spectroscopy (b) plot of RB absorbance 471 
against time for experiments performed in (a) ■ = wells pre-treated with US and ♦ = wells not 472 





























Figure 6  Whole body bioluminescent images of mice bearing 0.5 cm2 wounds infected with 477 
P.aeruginosa and receiving (i) no treatment (ii) ultrasound only (iii) RB-C(KLAKLAK)2 only or 478 
(iv) SDT, with images recorded immediately before, 1 h and 24 h after treatment.  479 
